Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 89, Issue 2, 2014, Pages 284-291

  Chiorean, E Gabriela ^a,b   Schneider, Bryan P ^a   Akisik, Fatih M ^c   Perkins, Susan M ^c   Anderson, Stephen ^c   Johnson, Cynthia S ^c   Dewitt, John ^c   Helft, Paul ^a   Clark, Romnee ^a   Johnston, Erica L ^a   Spittler, A John ^a   Deluca, Jill ^a   Bu, Guixue ^c   Shahda, Safi ^a   Loehrer, Patrick J ^a   Sandrasegaran, Kumar ^c   Cardenes, Higinia R ^c  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; PHARMACODYNAMICS; RADIOTHERAPY;

CONCURRENT RADIATION THERAPY; DYNAMIC CONTRAST ENHANCED MRI; GASTROINTESTINAL TOXICITIES; INTENSITY MODULATED RADIATION THERAPY; LOCALLY ADVANCED PANCREATIC CANCERS; MAXIMUM TOLERATED DOSE; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISMS;

TOXICITY;

GEMCITABINE; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN A;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RASH; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; VERY ELDERLY; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; INDUCTION CHEMOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NIACINAMIDE; PANCREATIC NEOPLASMS; PHENYLUREA COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RADIOTHERAPY, INTENSITY-MODULATED; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84899903717     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.02.024     Document Type: Article

References (20)

1. J. Karar, and A. Maity Modulating the tumor microenvironment to increase radiation responsiveness Cancer Biol Ther 8 2009 1994 2001
2. C. Timke, H. Zieher, and A. Roth et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy Clin Cancer Res 14 2008 2210 2219
3. C.H. Crane, K. Winter, and W.F. Regine et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411 J Clin Oncol 27 2009 4096 4102
4. M.I. Koukourakis, A. Giatromanolaki, and H. Sheldon et al. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: Vasculature-independent radiosensitizing effect of bevacizumab Clin Cancer Res 15 2009 7069 7076
5. E.J. Bernhard, E.J. Stanbridge, and S. Gupta et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines Cancer Res 60 2000 6597 6600
6. J.P. Plastaras, S.H. Kim, and Y.Y. Liu et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation Cancer Res 67 2007 9443 9454
7. A.W. Suen, S. Galoforo, and B. Marples et al. Sorafenib and radiation: A promising combination in colorectal cancer Int J Radiat Oncol Biol Phys 78 2010 213 220
8. X.F. Dai, J. Ding, and R.G. Zhang et al. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway Int J Radiat Biol 89 2013 724 731
9. S. Laban, L. Steinmeister, and L. Gleissner et al. Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation Radiother Oncol 109 2013 286 292
10. A.T. Wild, N. Gandhi, and S.T. Chettiar et al. Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma PLoS One 8 2013 e65726
11. B.P. Schneider, M. Wang, and M. Radovich et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 J Clin Oncol 26 2008 4672 4678
12. M.F. Akisik, K. Sandrasegaran, and G. Bu et al. Pancreatic cancer: Utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy Radiology 256 2010 441 449
13. P.S. Tofts, G. Brix, and D.L. Buckley et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols J Magn Reson Imaging 10 1999 223 232
14. H.L. Kindler, D. Niedzwiecki, and D. Hollis et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303) J Clin Oncol 28 2010 3617 3622
15. A. Goncalves, M. Gilabert, and E. Francois et al. BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer Ann Oncol 23 2012 2799 2805
16. B.P. Schneider, F. Shen, and K.D. Miller Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Lancet Oncol 13 2012 e427 e436
17. V. Formica, R. Palmirotta, and G. Del Monte et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab Int J Colorectal Dis 26 2011 143 151
18. J.P.B. O'Connor, A. Jackson, and G.J.M. Parker et al. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies Nat Rev Clin Oncol 9 2012 167 177
19. P.J. Loehrer, Y. Feng, and H. Cardenes et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreas cancer: An Eastern Cooperative Oncology Group trial J Clin Oncol 29 2011 4105 4112
20. J.M. Meyer, K.S. Perlewitz, and J.B. Hayden et al. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates Clin Cancer Res 19 2013 6902 6911